Search PubMed⌕ Search

Biomedical subjects

H C Neu

Publications and source records attributed to H C Neu.

At least 307 records · Page 17Linked to original sources
PubMed1981

Pharmacology of ceftizoxime compared with that of cefamandole.

The pharmacokinetics of ceftizoxime, a new beta-lactam antibiotic, were studied in normal, male volunteers and compared with the pharmacokinetics of cefamandole. After administration of 500 mg intramuscularly, ceftizoxime produced a peak level of 13.7 +/- 1 microgram/ml, compared with 13.2 +/- 1.6 microgram/ml for cefamandole. At 4 h, the serum level of ceftizoxime was 4.8 micrograms/ml, and that of cefamandole was 1.9 microgram/ml. At 8 h, ceftizoxime was still detected at 0.73 microgram/ml, whereas cefamandole was not. The half-life of ceftizoxime after intramuscular administration was 1.7 h, compared with 1 h for cefamandole. Serum levels of ceftizoxime and cefamandole after 1 g infused over 30 min were 84 and 88 micrograms/ml, respectively. At 5 h cefamandole was not detectable, whereas ceftizoxime had a serum level of 4.5 micrograms/ml and, at 7 h, 2.1 micrograms/ml. The half-life of ceftizoxime was 1.9 h, compared with 0.78 h for cefamandole. Urinary recovery of ceftizoxime after intramuscular and intravenous administration was 70 and 80%, respectively, compared with 78 and 73% for cefamandole.

Adult↗
PubMed1981

Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

The pharmacokinetics of moxalactam were determined in eight patients with end stage renal disease who were undergoing chronic hemodialysis. The mean half-life of moxalactam in the interdialysis period was 19 h, with a range of 9 to 30 h. The mean half-life of moxalactam during dialysis was 4 +/- 0.58 h. Serum levels of 30 +/- 10 micrograms/ml were present 24 h after a 1-g dose in the interdialysis period. A dose of 1 g at the end of each dialysis period in patients undergoing thrice-weekly hemodialysis would provide levels far in excess of the minimal inhibitory levels against Enterobacteriaceae.

Adult↗
PubMed1981

Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

The in vitro activities of gentamicin, tobramycin, amikacin, azlocillin, carbenicillin, mezlocillin, piperacillin, ticarcillin, cefotaxime, ceftizoxime, cefoperazone, cefsulodin, moxalactam, ceftazidime, ceftriaxone, and N-formimidoyl thienamycin were measured against 62 isolates of Pseudomonas aeruginosa obtained from patients with cystic fibrosis. Ceftazidime and N-formimidoyl thienamycin were the most active of these agents.

Anti-Bacterial Agents↗
PubMed1981

Rapid, reproducible enzyme immunoassay for tobramycin.

An enzyme immunoassay for tobramycin utilizing glucose 6-phosphate dehydrogenase was compared with the radioimmunoassay. The enzyme immunoassay for tobramycin was accurate, specific, and easily performed. It offers an alternative method for assaying aminoglycosides and could be used in institutions that use the enzyme immunoassay to assay other drugs.

Anti-Bacterial Agents↗
PubMed1981

Acute interstitial nephritis due to amoxicillin therapy.

Acute interstitial nephritis (AIN) has been reported in association with therapy with a number of drugs. We report a patient who developed drug-related AIN while receiving intravenous amoxicillin therapy. The patient developed rash, secondary temperature elevation, and eosinophilia in association with nonoliguric renal failure. Renal biopsy showed evidence for AIN and the renal failure was responsive to corticosteroid therapy. AIN may occur in patients receiving any drug of the penicillin class. This reversible form of acute renal failure must not be overlooked in patients with other forms of renal disease.

Acute Disease↗
PubMed1981

Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.

The pharmacokinetics of intravenously administered cefotaxime were studied in 11 patients with creatinine clearances of less than 7 ml/min who were undergoing chronic hemodialysis. Eight were studied during dialysis, and 3 were studied between dialyses. Pharmacokinetic parameters were determined using a two-compartment linear model. The serum half-life of cefotaxime off dialysis ranged from 1.48 to 3.78 hr. The half-life during dialysis was 2.52 +/- 0.34 hr. There was a 28% reduction in serum concentration per hour. A dosage schedule for the use of intravenously administered cefotaxime in patients undergoing hemodialysis is presented.

Adult↗
PubMed1981

Clinical evaluation of piperacillin therapy for infection.

Piperacillin sodium, a semisynthetic penicillin that inhibits many Klebsiella and Pseudomonas aeruginosa organisms resistant to carbenicillin, was used to treat 41 episodes of infection in 35 patients. Infectious sites included lungs, urinary tract, and tissue, including peritonitis. Seven patients had bacteremia. Clinical and bacteriological cures were achieved in 85% of infections. Cure was achieved with piperacillin in patients infected with carbenicillin-resistant P aeruginosa and Klebsiella organisms. Adverse effects were minor and included rash in two patients. Serum levels were easily maintained above the inhibitory levels for susceptible organisms. Piperacillin was a safe, well-tolerated, and effective antimicrobial agent.

Adolescent↗
PubMed1981

Aspergillus endocarditis in children: case report and review of the literature.

Aspergillus fumigatus endocarditis developed in a 2 1/2-year-old girl after repair of tetralogy of Fallot. There have been 14 other cases of Aspergillus endocarditis in children described in the literature. Fever and embolic phenomenon, particularly to the CNS, were the most common presenting manifestations. Consumptive coagulopathy developed in this patient as it has in other children and should suggest the diagnosis of Aspergillus endocarditis inasmuch as blood cultures are uniformly negative. Antemortem diagnosis was made in four of 15 patients. Only one patient survived the infection. Environmental surveillance is crucial when a case is encountered. Survival of the infected patient occurs only with early diagnosis and surgical removal of the infected tissue.

Aspergillosis↗
PubMed1980

Optimal antibiotic therapy in bronchopulmonary infections.

Therapy of bronchopulmonary infections has evolved in the past 30 years. Only in the therapy of pneumococcal infections have, precise dosage programs been developed. Therapy of pneumococcal infection is optimal with penicillin G in low dosage. None of the newer agents has altered morbidity or mortality. The best agent for the treatment of pneumonia due to Staphylococcus aureus or members of the Enterobacteriaceae has not been established. Use of combination therapy consisting of an anti-Pseudomonas penicillin and an aminoglycoside has been shown to offer the greatest success in the treatment of Pseudomonas pulmonary infections. The optimal antibiotic and dosage program for the treatment of acute bacterial exacerbations of chronic bronchitis has yet to be defined. Further comparative studies of the chemotherapy of pulmonary infections are necessary.

Aminoglycosides↗
PubMed1980

Fluid management in Haemophilus influenzae meningitis.

The fluid management of 50 children with Haemohpilus influenzae type B meningitis was reviewed. Clinical hydration status on admission, serum sodium values, and overall fluid balance was assessed to determine the contribution of empiric fluid restriction in preventing the development of syndrome of inappropriate antidiuretic hormone (SIADH). Thirty-three of 50 patients were well hydrated on admission. Sixteen of 50 patients (32%) initially had signs of dehydration and five out of 16 were in shock. Only two patients had evidence of SIADH. Twenty patients were empirically fluid restricted, including one who proceeded to develop SIADH; thirteen were not fluid restricted, and sixteen who were dehydrated received replacement fluids in addition to the usual maintenance fluids. None of these patients developed SIADH. As fluid depletion was more common than excessive fluid retention in our patients, empiric fluid restrictions could not be justified. Careful, individualized monitoring of the clinical state of hydration, electrolytes and osmolaities is suggested to guide the fluid management in these patients.

Child, Preschool↗
PubMed1980

Deaths from nosocomial infections: experience in a university hospital and a community hospital.

To assess the importance of nosocomial infections as a contributory cause of death in patients who die in the hospital, we studied the hospital course of 100 consecutive patients who died at Columbia-Presbyterian Medical Center and 100 consecutive patients who died at Hackensack Hospital. The epidemiologic patterns of infection were similar although the institutions provide care for different types of patients. There were 88 nosocomial infections in 63 patients. When the nosocomial infection was causally related or contributed to death, infection of the lower respiratory tract was predominant in 31 of 52 (60 per cent) instances. When the nosocomial infection was unrelated to death, urinary tract infection was predominant in 13 of 36 (36 per cent) infections. Among those who died with nosocomial infection, 42 of 63 (67 per cent) patients were terminal on admission and were typically in their 60's with metastatic carcinoma. The 21 patients who were not terminal on admission were typically in their late 70's and had complications of arteriosclerotic cardiovascular disease. Pneumonia was the most frequent nosocomial infection related to death. There is need to devise a pneumonia prevention program that identifies those at high risk and reduces the chance of aspiration of pharyngeal secretions and spread of virulent bacteria from person to person.

Adolescent↗
PubMed1980

Intravenous azlocillin kinetics in patients on long-term hemodialysis.

The kinetics of the antipseudomonas penicillin, azlocillin, was studied after intravenous injection in 9 patients with creatinine clearance under 7 ml/min. All were on long-term hemodialysis; 3 were also studied during a dialysis-free period. Kinetic parameters were derived using a 2-compartment open model. The mean serum azlocillin half-life (t 1/2) was 1.93 hr in patients on dialysis and approximately 5 hr off dialysis. Thirty percent of the dose was recovered in the dialysate during a 4-hr period. An approach to the use of azlocillin in patients undergoing dialysis is presented.

Adult↗
PubMed1980

Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.

The kinetics of cefotaxime, a cephalosporin with an unusually broad antibacterial spectrum, were examined in humans after intravenous bolus injection, intravenous infusion every 6 hr for 14 days, and intramuscular injection every 8 hr for 10 days. Mean peak serum level after bolus injection of 500 mg was 37.9 microgram/ml; after 1 gm, 102.4 microgram/ml; and after 2 gm, 214.1 microgram/ml. The half-life (t1/2) was 1 hr for the 3 doses. Total serum clearance was the same for all doses. Overall excretion was 50% to 60%; part of the drug was excreted as the desacetyl derivative. After multiple intravenous infusion the elimination rate constants and t1/2 were the same on days 1 and 15. Assayable levels were present on all days 5 min before injection of a dose. Multiple intramuscular injections of 500 mg produced serum levels of 9.2 to 11.9 microgram/ml. The t1/2 was 0.93 hr. Mean serum levels at 8 hr ranged from 0.08 to 0.55 microgram/ml. Serum levels produced by intravenous infusion or intramuscular injection were inhibitory for most (90%) aerobic gram-positive and gram-negative organisms susceptible to cefotaxime.

Adult↗